Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DVAX Dynavax Technologies Corp
- Stocks
- Healthcare
- NASDAQ: DVAX
Price (delayed)
$10.42
Market cap
$1.25B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.49
Enterprise value
$1.49B
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of
Highlights
The company's gross profit rose by 28% YoY and by 6% QoQ
DVAX's revenue is up by 25% year-on-year and by 6% since the previous quarter
DVAX's quick ratio is down by 24% YoY but it is up by 9% QoQ
Dynavax Technologies's equity has decreased by 14% YoY and by 11% from the previous quarter
Dynavax Technologies's debt has increased by 14% from the previous quarter and by 14% YoY
Key stats
What are the main financial stats of DVAX
Market
Valuations
Earnings
Shares outstanding
120.08M
Market cap
$1.25B
Enterprise value
$1.49B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
4.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.04
Revenue
$294.62M
Gross profit
$242.37M
Operating income
-$9.98M
Net income
-$60.07M
EBIT
-$48.73M
EBITDA
-$40.59M
Free cash flow
$54.02M
Per share
Balance sheet
Liquidity
EPS
-$0.49
EPS diluted
-$0.52
Free cash flow per share
$0.43
Book value per share
$4.28
Revenue per share
$2.36
TBVPS
$7.56
Total assets
$945.93M
Total liabilities
$414.99M
Debt
$286.03M
Equity
$530.94M
Working capital
$747.59M
Debt to equity
0.54
Current ratio
11.93
Quick ratio
10.5
Net debt/EBITDA
-5.77
Margins
Efficiency
Dividend
EBITDA margin
-13.8%
Gross margin
82.3%
Net margin
-20.4%
Operating margin
-3.4%
Return on assets
-6%
Return on equity
-9.8%
Return on invested capital
-4.4%
Return on capital employed
-5.6%
Return on sales
-16.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DVAX stock price
How has the Dynavax Technologies stock price performed over time
Intraday
6%
1 week
8.32%
1 month
1.07%
1 year
-8.52%
YTD
-18.4%
QTD
-19.66%
Financial performance
How have Dynavax Technologies's revenue and profit performed over time
Revenue
$294.62M
Gross profit
$242.37M
Operating income
-$9.98M
Net income
-$60.07M
Gross margin
82.3%
Net margin
-20.4%
DVAX's operating income has dropped by 142% since the previous quarter but it has soared by 59% year-on-year
The company's operating margin has shrunk by 127% QoQ but it has surged by 67% YoY
The company's gross profit rose by 28% YoY and by 6% QoQ
DVAX's revenue is up by 25% year-on-year and by 6% since the previous quarter
Price vs fundamentals
How does DVAX's price correlate with its fundamentals
Growth
What is Dynavax Technologies's growth rate over time
Valuation
What is Dynavax Technologies stock price valuation
P/E
N/A
P/B
2.43
P/S
4.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.04
DVAX's P/B is 63% below its 5-year quarterly average of 6.6 and 7% below its last 4 quarters average of 2.6
Dynavax Technologies's equity has decreased by 14% YoY and by 11% from the previous quarter
The P/S is 33% less than the 5-year quarterly average of 6.6 and 22% less than the last 4 quarters average of 5.7
DVAX's revenue is up by 25% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Dynavax Technologies business performance
Dividends
What is DVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DVAX.
Financial health
How did Dynavax Technologies financials performed over time
Dynavax Technologies's total assets is 128% higher than its total liabilities
DVAX's quick ratio is down by 24% YoY but it is up by 9% QoQ
Dynavax Technologies's current ratio has decreased by 22% YoY but it has increased by 10% QoQ
Dynavax Technologies's debt is 46% less than its equity
The debt to equity has grown by 32% YoY and by 29% from the previous quarter
Dynavax Technologies's equity has decreased by 14% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.